An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 01 Jan 2017
Price : $35 *
At a glance
- Drugs Pasireotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Expanded access
- Acronyms ACCESS
- Sponsors Novartis Pharmaceuticals
- 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society.
- 05 Nov 2015 Status changed from completed to recruiting, as reported by ClinicalTrials.gov record
- 05 Jun 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.